SEATTLE, Wash and VANCOUVER, British Columbia, August 8, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today provided an update on the cytisine clinical development program and announced second quarter 2018 financial results. Recent Achieve Highlights Announced plans to…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, August 2, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it will report its second quarter 2018 financial results on Wednesday, August 8, 2018. Company management will host a…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, July 11, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting conducted with the United States (U.S.) Food and Drug Administration…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, June 26, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company, today announced positive results from a series of drug metabolism, drug-drug interaction and transporter studies with cytisine, the Company’s product candidate being evaluated as an aid to smoking cessation. The study demonstrated that cytisine has…
/Read More
SEATTLE, Wash. And VANCOUVER, British Columbia, June 19, 2018 – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of…
/Read More